Search
Displaying 41–50 of 585 for “Retinitis pigmentosa”
-
Foundation News
A new partnership with A Race Against Blindness brings a spring 2026 luxury vehicle fundraiser to support people living with RP and Bardet-Biedl syndrome.
-
Recording Available: Insights Forum | Friday, December 12, 2025
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on December 12, 2025.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Fighting RP on the Foundation’s Frontline
Beacon StoriesMichelle Glaze, the Foundation’s associate director of professional outreach, shared her personal story of being diagnosed with retinitis pigmentosa (RP) in the film ‘Decoding disease.‘ In her own words, Michelle also describes her journey with genetic testing and the Foundation Fighting Blindness’ impact on her life.
-
Information for affected individuals and their families about the role of genetic counseling.
-
Llura Liggett Gund Award Laureates
A distinguished group of scientists and clinicians has been recognized with this honor for their lasting contributions to the field.
-
Beacon's emerging XLRP gene therapy improves low-light vision in phase 3 trial
Research NewsBeacon plans to begin a rolling FDA submission for laru-zova later this year
.png)
